Cerevel Therapeutics
(NASDAQ) CERE
Cerevel Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$8.25M
Net Income (TTM)
$460.47M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
CERE News
CERE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cerevel Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
334
CEO
Ronald C. Renaud, Jr., MBA
Website
www.cerevel.comHeadquarters
Cambridge, MA 02141, US
CERE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-72%
Return on Capital
-39%
Return on Assets
-35%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$5.63M
Operating Income
$447.26M
EBITDA
$416.14M
Operating Cash Flow
$342.30M
Capital Expenditure
$3.81M
Free Cash Flow
$346.11M
Cash & ST Invst.
$990.97M
Total Debt
$480.78M
Cerevel Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$1.54M
-16.7%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
355
N/A
Net Income
$131.91M
-26.5%
EBITDA
$139.38M
-41.9%
Quarterly Fundamentals
Net Cash
$477.99M
+3.8%
Accounts Receivable
$4.96M
+55.0%
Inventory
$0.00
+100.0%
Long Term Debt
$364.79M
-0.4%
Short Term Debt
$3.52M
+16.1%
Return on Assets
-34.81%
N/A
Return on Invested Capital
-38.85%
N/A
Free Cash Flow
$119.94M
-25.9%
Operating Cash Flow
$119.67M
-26.1%